ClinicalTrials.gg
CompletedNCT06039826Updated Jul 26, 2024

A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese

A Phase 1 interventional study of LY3437943 and Ethinyl Estradiol in Overweight, sponsored by Eli Lilly and Company. Completed at 2 sites in United States. Open to female participants aged 40 Years to 60 Years. Per ClinicalTrials.gov, last updated 2024-07-26.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Jul 2024, 2 years 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
46
Allocation
Non-randomized
Ages
40 Years to 60 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing retatrutide in Overweight — none open to participants now, 3 under way, 3 of them phase 3. retatrutide · Overweight.

Enrollment
9th of 11
46 · median 338
Started
2023
with 4 others
Phase 1
3 of 11
none open now
Registered
8th of 11
by date
Lead sponsor
11 of 11
Eli Lilly and Company

Among the 11 studies testing retatrutide in Overweight, this one is the 9th largest by enrollment, is one of 5 that started in 2023, is one of 3 in phase 1, and was the 8th registered.

Overweight

3,613 studies on the registry are indexed under Overweight; 861 are open to participants now.

Browse Overweight studies →

Open to participants now

None of the 11 studies testing retatrutide in Overweight is open now. The open studies under Overweight, anywhere →

About retatrutide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 534 Overweight studies recruiting now, 159 (30%) set no upper age limit and 347 (65%) stop at 75 or younger; 64 take children under 18; 205 take healthy volunteers.

This study: 40 Years to 60 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing retatrutide in Overweight as a file.
02

Study summary

The main purpose of this study is to determine the effect of LY3437943 when administered subcutaneously on the levels of combined oral contraceptive (COC) ethinyl estradiol and drospirenone in the blood stream in postmenopausal female participants who are overweight or obese. The safety and tolerability of LY3437943 when administered with COC will also be evaluated. This study will last up to approximately 29 weeks for each participant.

03

Conditions studied

  • Overweight

Keywords

  • Pharmacokinetics
  • Obesity
  • Oral Contraceptive
04

Who can participate

Ages eligible
40 Years to 60 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • female participants
  • (BMI) within the range 27.0 to 40.0 kilograms per meter squared (kg/m²)

Exclusion criteria

Exclusion Criteria:

  • Have an unstable disease or a disease constituting a risk when taking the study intervention.
  • Have significant renal insufficiency
  • Have an important gastro-esophageal reflux disease, pyloric stenosis, gastroparesis or a history of gastric bypass surgery.
  • Have a history or presence of chronic or idiopathic acute pancreatitis.
  • Have a history of severe multiple or severe drug allergies.
  • Have a personal or family history of medullary thyroid carcinoma or have multiple endocrine neoplasia syndrome type 2
  • Have had any within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin or in situ carcinoma of the cervix that have been resected with no evidence of disease for 3 years
  • Have any form of diabetes mellitus other than type 2
  • Have type 2 diabetes with greater than or equal to 10% at screening
  • Have received an oral or transdermal patch hormone replacement therapy (HRT) within the last 1 month prior to screening or depot injectable HRT within the last 6 months
  • Have received any drug within the last month or 5 half-lives of this drug, whichever is longer, prior to screening. If the half-life of the previous investigational drug is unknown, the should be at least 3 months before screening
  • Show evidence of infection or positive HIV antibodies
  • Have evidence of, or test positive for, anti- virus antibody unless a confirmatory test for hepatitis C virus RNA is negative
  • Test positive for surface antigen. In case a hepatitis B virus DNA test was also performed recently and is positive, the participant should be excluded independently of the hepatitis B surface antigen test result. The hepatitis B core antibody test is not used to assess eligibility
  • Have acute or chronic hepatitis, or signs and symptoms of any other liver disease, or with significant abnormalities in laboratory liver tests
  • Have a fasting triglyceride level greater than 500 mg/dL at screening
  • Used any nicotine product including tobacco or nicotine replacement products within 1 month prior to screening or a positive cotinine test at screening. Are unable or unwilling to refrain from using such products during the study
  • Have donated at least 450 mL of blood within 8 weeks before screening or intend to donate blood during the study
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
46 participants (actual)

Study arms

  • Experimental
    LY3437943 + Combined Oral Contraceptive (COC)

    The COC ethinyl estradiol and drospirenone administered orally in combination with LY3437943 administered subcutaneously (SC).

    Drug: LY3437943 · Drug: Ethinyl Estradiol · Drug: Drospirenone

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from Time zero to 24 Hours Postdose (AUC0-24) of Ethinyl Estradiol

    PK: AUC0-24 of Ethinyl Estradiol

    Time frame: Predose on Day 1 up to 144 days postdose

  2. PK: Maximum Observed Concentration (Cmax) of Ethinyl Estradiol

    PK: Cmax of Ethinyl Estradiol

    Time frame: Predose on Day 1 up to 144 days postdose

  3. PK: Time of Maximum Observed Concentration (Tmax) of Ethinyl Estradiol

    PK: Tmax of Ethinyl Estradiol

    Time frame: Predose on Day 1 up to 144 days postdose

  4. PK: Area Under the Concentration Versus Time Curve from Time zero to 24 Hours Postdose (AUC0-24) of Drospirenone

    PK: AUC0-24 of Drospirenone

    Time frame: Predose on Day 1 up to 144 days postdose

  5. PK: Maximum Observed Concentration (Cmax) of Drospirenone

    PK: Cmax of Drospirenone

    Time frame: Predose on Day 1 up to 144 days postdose

  6. PK: Time of Maximum Observed Concentration (Tmax) of Drospirenone

    PK: Tmax of Drospirenone

    Time frame: Predose on Day 1 up to 144 days postdose

07

Study locations

2 sites
  • Qps-Mra, Llc
    South Miami, Florida 33143, United States
  • ICON Early Phase Services
    San Antonio, Texas 78209, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2023 to primary completion in Jul 2024, 9 months.

Of 212 industry-sponsored phase 1 interventional studies under Overweight, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 14. This study's 9 months is above that.

Counting every sponsor, half of 231 studies reached it within 9 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2023
First posted
Sep 15, 2023
StartActual
Sep 12, 2023
Primary completionActual
Jul 11, 2024
CompletionActual
Jul 11, 2024
Last update
Jul 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06039826
Responsible party
Sponsor
First posted
Sep 15, 2023
Start date
Sep 12, 2023
Primary completion
Jul 11, 2024
Completion
Jul 11, 2024
Last update
Jul 26, 2024

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Retatrutide · Ethinyl Estradiol · Drospirenone

Start the discussion